The actions of many hormones may be related to their capacity to increase adenyl cyclase activity in their target organs. The evidence indicating that catecholamines and glucagon augment myocardial contractility by enhancing the activity of myocardial adenyl cyclase is summarized. Furthermore, data are presented suggesting that the inotropic actions of epinephrine and glucagon ultimately may be due to an increase in sarcotubular calcium stores, an effect that appears to be related to activation of an adenyl cyclase pool localized in the sarcoplasmic reticulum. Other hormones that may alter contractility through actions on the adenyl cyclase-cyclic AMP system are thyroid hormone, histamine, prostaglandin, and acetylcholine. Chronic cardiac decompensation in both the experimental animal and in man diminishes the effectiveness of glucagon as an inotropic agent and interferes with the mechanisms by which glucagon acts to enhance the activity of myocardial adenyl cyclase, changes that may be causally interrelated. Although an understanding of the adenyl cyclase system would seem to be extremely important for an understanding of the basic mechanisms responsible for modulating the intensity of the contractile state of the heart, further investigations are necessary for complete validation of this hypothesis. 
SINCE Sutherland and Rall' first reported that the glycogenolytic effect of epinephrine and glucagon in the liver was associated with the formation of cyclic AMP (adenosine 3',5'-monophosphate), the results of a large series of investigations have led to the construction of a hypothetical model of hormonal action, which is illustrated schemat-ically in figure 1. This model is based on the concept that the actions of many hormones may be related to their capacity to increase the activity of adenyl cyclase, an enzyme that catalyzes the conversion of ATP to cyclic AMP, thereby increasing the intracellular levels of cyclic AMP. The rise in cyclic AMP concentration is believed to initiate a series of intermediate steps, as yet undefined, which ultimately result in the physiologic response characteristic of the target organ. The other major intrinsic regulator of cyclic AMP is phosphodiesterase, an enzyme that catalyzes the breakdown of cyclic AMP to inactive 5'-AMP. Unlike adenyl cyclase, which is located in the cell membrane, phosphodiesterase is 437 Figure 1 Schematic diagram of the adenyl cyclase-cyclic AMP system. Abbreviations: ATP = adenosine triphosphate; AMP = adenosine monophosphate.
distributed mainly in the soluble fractions of the cell. It is inhibited by the methylxanthines, a property that is utilized in several assays in vitro of adenyl cyclase and cyclic AMP. Theoretically, a hormone could alter the intracellular level of cyclic AMP by affecting either its rate of synthesis or degradation. To date, however, only adenyl cyclase activity has been found to be altered by hormonal action.
Important in this scheme of hormone action is the receptor, defined as that constituent of the target cell that first interacts with the hormone. Although initially it was suggested that adenyl cyclase itself was the receptor, recent evidence has suggested that this enzyme is in fact distal to the receptor, as diagrammatically depicted in figure 1 . On the basis of currently available information, it would appear that at least some, if not all, receptors are hormone-specific. For example, ACTH (adrenocorticotropin) stimulates adenyl cyclase activity in the adrenal gland, and thyroid stimulating hormone activates adenyl cyclase located in the thyroid, but neither of these hormones increases the activity of myocardial adenyl cyclase.2 Separate hormone-specific receptors may even be present in the same tissue, as evidenced by the finding that, although both the catecholamines and glucagon activate myocardial adenyl cyclase and augment myocardial contractility, beta receptor blocking agents inhibit only the effects of catecholamines; they do not interfere with the actions of glucagon. [2] [3] [4] The demonstration that adenyl cyclase is present in a particular tissue and that a given hormone can increase the enzyme's activity provides suggestive evidence that the adenyl cyclase-cyclic AMP system serves as the mediator for the actions of that particular hormone on its target tissue. However, before a reasonable degree of credibility can be attributed to such a hypothesis four criteria, as defined by Sutherland and his coworkers,5 should be fulfilled: (1) the hormone should activate adenyl cyclase in broken cell preparations; (2) it should increase the concentration of cyclic AMP in the intact tissue; (3) the physiologic response it evokes in its target organ should be enhanced by phosphodiesterase inhibitors; and (4) this physiologic response should be reproduced by cyclic AMP or one of its more lipid-soluble derivatives. A large body of experimental data exists relating to the role of cyclic AMP as an intracellular mediator in all of the tissues listed in table 1. The biologic role of cyclic AMP in mediating the cardiac effects of catecholamines and other agents was the subject of an extensive review published in this journal in 1968.5 In the intervening years much new information concerning this subject has been acquired; it is the purpose of the present review to reappraise the role of the adenyl cyclase-cyclic AMP system and its relation to myocardial function in both normal and diseased hearts.
Cardiac Effects of Catecholamines
The cardiac effects of several hormones have been postulated to involve an interaction with adenyl cyclase. In particular, the, catecholamines have been the subject of intensive investigation. As regards the adequacy of the evidence indicating a role of adenyl cyclasecyclic AMP in mediating the inotropic effects of the catecholamines, these agents have been found to increase both the concentration of cyclic AMP in the intact heart612 and the accumulation of cyclic AMP in broken cell preparations of human, cat, dog, and rat Figure 2 Glucagon and norepinephrine concentration-response curves in normal cats. The values represent the mean + SE of eight samples from three cats for the glucagon data, and the mean + SE of [10] [11] [12] [13] [14] [15] samples from five cats for the norepinephrine data. Some doubt has been cast on this hypothesis, however, by the finding that, although glucagon increases peak developed tension and rate of tension development (dT/dt) in the isometrically contracting cat papillary muscle, it produces either no change or a prolongation of the time required to achieve peak tension.3' 4 22 This contrasts to the Circulation, Volume The effects of theophylline pretreatment on the response of papillary muscles to crystalline glucagon. The differences in developed tension between the control muscles and those pretreated with glucagon were significant at a concentration of glucagon of Thus, although no significant decrease in time to peak tension development occurs at peak glucagon effect, equipotent concentrations of norepinephrine and dibutyryl cyclic AMP also fail to alter time to peak tension development23 ( fig. 6 ). Moreover, when the inotropic effects of glucagon are potentiated by theophylline so that peak tension development approaches that achieved by norepinephrine and dibutyryl cyclic AMP, time to peak tension development is reduced appreciably21 ( fig. 6 ). These findings offer an explanation for a major objection to the hypothesis that the adenyl cyclase-cyclic AMP system is responsible for mediating the inotropic effects of glucagon.
Although it would appear that norepinephrine and glucagon act through a common system in the heart, each hormone seems to exert its cellular effects by first interacting with a different receptor. This conclusion is based on the observation that, while propranolol inhibits the enzymatic and mechanical effects of norepinephrine on the heart, it alters neither the increase in adenyl cyclase activity nor the positive inotropic effects caused by glucagon.24
Cardiac Effects of Histamine, Prostaglandin, and Acetylcholine Preliminary evidence also exists implicating a role for the adenyl cyclase-cyclic AMP system in the cardiovascular effects of histamine,2 26 prostaglandin,27 and acetylcholine.13 28 The acetylcholine-adenyl cyclase interaction may be unique in that choline esters reduce rather than increase the rate of cyclic AMP production in particulate cardiac preparations. When administered in concentrations that do not liberate endogenous catecholamines, acetylcholine and other choline esters produce a negative inotropic effect [28] [29] [30] which is more pronounced in atrial than in ventricular muscle.28 These findings would, therefore, suggest that the negative Relationship between changes in time required to achieve peak tension to changes in developed tension in cat papillary muscles contracting isometrically. Each (reverse T3), and 3,3'-diiodothyronine also increased the accumulation of cyclic AMP, but 3,5-diiodo-l-thyronine, l-thyronine, 3,5-diiodotyrosine, monoiodotyrosine, and tyrosine were inactive. It would appear, therefore, that iodination of the 3' position of the thyronine moiety is an important structural characteristic necessary for enhancing the activity of myocardial adenyl cyclase.
Although these results suggest that thyroid hormone might enhance myocardial contractility by stimulating myocardial adenyl cyclase, this hypothesis remains unproven. Evidence against such a mechanism is provided by the findings that thyroid hormones do not exert direct inotropic effects on isolated papillary muscles ( In addition to the direct myocardial effects of thyroid hormone, it has been suggested that the responsiveness of the heart to catecholamine stimulation is greatly affected by the level of thyroid activity, hyperthyroidism increasing and hypothyroidism decreasing myocardial sensitivity to catecholamines.41 42 However, recent data from many laboratories using a variety of experimental models indicate that the cardiac effects of catecholamines are not altered under conditions of thyroid hormone excess or deficiency.4 3 4 To investigate the biochemical analog of this question, we examined the effects of norepinephrine on adenyl cyclase activity in particulate fractions of heart homogenates from hyperthyroid and hypothyroid cats.39 Neither the threshold concentration of norepinephrine nor the concentration producing half-maximal activity was found to be altered in hyper-or hypothyroidism. When the effects of norepinephrine on the contractile response of the papillary muscles derived from the same hearts were studied, no differences from normal were found. Thus, the biochemical data correlated with the physiologic responses. It was of interest, however, that, although the sensitivity of adenyl cyclase to norepinephrine stimulation was unaltered in hypothyroidism (i.e., threshold concentrations of norepinephrine and that concentration producing halfmaximal activity were similar), the nmximal capacity of norepinephrine to generate cyclic AMP was decreased in the hypothyroid hearts. Since the papillary muscles exhibited normal contractile responsiveness to norepinephrine, it would appear that the amount of cyclic AMP capable of being generated by norepinephrine in the heart is in excess of that needed to achieve the normal physiologic response. Similarly, it also has been found that intracellular levels of cyclic AMP produced by ACTH in the adrenal gland can be increased to concentrations far in excess of that necessary to generate a peak steroidogenic effect. 47 The apparent excess capacity demon strated in these two tissues might constitute an adenyl cyclase reserve, an interpretation that is not unreasonable considering the profound importance of this enzyme. Alternatively, there could be separate pools of adenyl cyclase and cyclic AMP, each responsible for modulating a different cellular function. In the heart hypothyroidism might selectively decrease some pools, but not that responsible for mediating the effects of catecholamines on contractility. Finally, it still is possible that changing levels of adenyl cyclase activity or cyclic AMP concentration do not in fact alter myocardial contractility, and that the changes in enzyme activity and contractility we observe represent associated, but causally unrelated, events. If this is the case, the observation cited alone could be interpreted as being compatible with such a hypothesis.
Adrenergic Stimulation
The observation that such antiadrenergic drugs as propranolol, reserpine, and guanethidine reduce the heart rate and relieve some of the symptoms of hyperthyroid patients sug-gests that if the sensitivity of the hyperthyroid heart to adrenergic stimuli is not enhanced, then at least a portion of the hyperdynamic circulatory state of hyperthyroidism is attributable to excessive levels of adrenergic stimulation. That excessive adrenergic stimulation cannot account for all of the circulatory effects seen in hyperthyroidism is evidenced by the findings that antiadrenergic drugs do not reduce the heart rate of hyperthyroid patients to levels achieved in similarly treated normal subjects.48 4 In addition to their role in inhibition of adrenergic stimuli, we considered the possibility that these sympatholytic drugs might have a specific antithyroid effect in terms of thyroid hormone's actions on the adenyl cyclase system. That such a mechanism is not operative was suggested by our findings that neither pretreatment of cats with reserpine nor the direct addition of reserpine, guanethidine, or propranolol to the incubation mixtures diminished the increase in adenyl cyclase activity produced by thyroid hormone.36 50 Furthermore, the observation that propranolol does not inhibit the effects of thyroid hormone on adenyl cyclase suggests that the receptor responsible for initiating this 
Use of Glucagon in Cardiac Failure
The positive inotropic effects exhibited by glucagon in normal man and animals led to its use in the treatment of cardiac failure in man. Although the results of initial studies in which glucagon was administered to patients with cardiac decompensation were encouraging,5 [1] [2] [3] [4] with more extensive experience it became apparent that the beneficial effects of this drug in patients with chronic cardiac decompensation were, at best, inconsistent.55-57 Since unequivocal increases of myocardial contractility were demonstrated to occur in patients with no or mild impairment of cardiac function,5' we directed our attention to the possibility that chronic cardiac failure itself might alter the responsiveness of the heart to glucagon. We first approached this problem experimentally by banding the pulmonary artery of cats to produce isolated right ventricular failure. Four to 145 days later, right ventricular papillary muscles were removed and their responses to norepinephrine and glucagon were compared to the responses of papillary muscles obtained from normal cats. It was found that while the positive inotropic effects of norepinephrine wvere undiminished by chronic heart failure, the papillary muscles obtained from the chronically failing animals did not respond to glucagon.22 Likewise, the capacity of norepinephrine to enhance the activity of adenyl cyclase in particulate preparations obtained from the right ventricles of the cats in chronic right ventricular failure was undiminished, but that to glucagon was abolished ( fig. 7, left  panel) . In contrast, relatively normal contractile and adenyl cyclase responses to glucagon were found in cats subjected to isolated right ventricular failure for only 30 min. These results suggest that chronic heart failure diminishes the effectiveness of glucagon as an inotropic agent and interferes with the mechanisms by which glucagon acts to enhance the activity of myocardial adenyl cyclase, changes which presumably are causally interrelated.
In view of a variety of studies demonstrating that isolated right ventricular failure is associated with biochemical and functional abnormalities in the unstressed left ventricle,5862 we also determined whether or not the defect in the responsiveness of adenyl cyclase to glucagon was confined to the failing right ventricle, or was a more generalized phenomenon.63 When the effects of chronic isolated right ventricular failure on the capacity of left ventricular adenyl cyclase to respond to glucagon stimulation were assessed, we found results that were similar to those previously obtained in the right ventricle, i.e., the concentration-response curve to glucagon was markedly depressed (fig. 7 , middle panel). However, concentration-response curves to glucagon utilizing particulate preparations of livers of normal and failure cats were identical ( fig. 7, right panel) . Thus, although the defect in adenyl cyclase responsiveness to glucagon is not a generalized phenomenon, isolated right ventricular failure leads not only to a decreased capacity of right ventricular adenyl cyclase to respond to glucagon stimulation, but also to an impairment of the responsiveness of adenyl cyclase derived from the unstressed left ventricle.
The factors responsible for the failureCirculation, Volume XLIII, induced impairment of the adenyl cyclase system to respond to glucagon are unknown. Since chronic heart failure does not alter the response of myocardial adenyl cyclase to norepinephrine, the adenyl cyclase system itself would not appear to be changed by chronic heart failure. The lack of an effect of glucagon on myocardial adenyl cyclase derived from cats with chronic failure must, therefore, be due either to an alteration of the characteristics of the glucagon receptor that specifically impairs its ability to bind glucagon, or to an uncoupling of the receptor to adenyl cyclase. The cause of such a defect could be locally induced by a metabolic or mechanical change occurring in the failing heart; alternatively, the defect could be caused by a blood-borne factor elaborated as a result of the circulatory changes present during cardiac failure. In this regard, proteolytic enzymes have been found to be released into the circulation during hemorrhagic shock produced in the experimental animal. Finally, we might briefly consider the available evidence concerning the possible subcellular mechanism through which cyclic AMP exerts its physiologic effects in the heart. A sudden increase in the calcium available to the contractile apparatus is believed by many to be responsible for coupling the process of electrical excitation to that of myocardial contraction. Although the exact location of the calcium pool responsible for initiating contraction is unknown, it has been suggested that calcium stored in the sarcoplasmic reticulum might subserve such a role. It has been hypothesized further that an increase in sarcotubular calcium stores may augment contractility by making more calcium available to the contractile proteins. Recently, in studies performed in collaboration with Dr. Mark Entman, an adenyl cyclase system was identified in the microsomal fraction of the canine heart.68 69 This fraction actively accumulates calcium and is thought to represent sarcoplasmic reticulum. The adenyl cyclase associated with it responds to epinephrine, norepinephrine, and glucagon, with half-maximal activity for the catecholamines being approximately 1 x 10-5 m, and for glucagon, 1 X 10-7 M. The responses to epinephrine and norepinephrine are inhibited by propranolol; those to glucagon are not. Of further interest, we found that the catecholamines and glucagon increase calcium accumulation by this microsomal fraction; the effect of the catecholamines is blocked by propranolol, but that of glucagon is not. Significantly, cyclic AMP increases calcium accumulation to a level as great as that seen with glucagon and epinephrine. Similar results have been obtained by other investigators.70 71 It is possible, therefore, that the basic mechanism by which the catecholamines and glucagon exert their positive inotropic effects involves stimulation of an adenyl cyclase enzyme closely associated with the sarcoplasmic reticulum. This, we hypothesize, leads to increased levels of cyclic AMP, which in turn causes an augmentation of sarcotubular calcium pools, and thereby causes an increase in myocardial contractility.
Having outlined this hypothesis, we want to emphasize that there are appreciable limitations inherent in current methods used for isolating sarcoplasmic reticulum. Conclusions based on the above results can, therefore, only be regarded as tentative. Indeed, using somewhat different techniques for isolating sarcoplasmic reticulum from the canine heart, Dhalla and coworkers were unable to demonstrate an effect of epinephrine on calcium accumulation.72 It is apparent that the final definition of the ultimate subcellular mechanism responsible for producing the positive inotropic effects of catecholamines or glucagon must await the development of more satisfactory procedures for isolating and identifying cardiac sarcoplasmic reticulum.
Concluding Remarks
In conclusion, an understanding of the adenyl cyclase system would seem to be extremely important to an understanding of the basic mechanisms responsible for modulating the intensity of the contractile state of the heart. However, some note of caution should be injected regarding an unquestioned acceptance of the role of cyclic AMP in altering myocardial contractility. In a very interesting preliminary communication, Kjekshus and Sobel73 demonstrated in an isolated guinea pig heart preparation that cyclic AMP alone activated phosphorylase only minimally and did not alter contractility. When administered in the presence of 3% dimethylsulfoxide, however, phosphorylase activation increased markedly, a finding suggesting that in the presence of dimethylsulfoxide cyclic AMP entered the cell. Nevertheless, contractility still was unaltered. This apparent dissociation between the capacity of cyclic AMP to activate phosphorylase and to enhance contractility was interpreted as supporting the view that the positive inotropic effects of the catecholamines may not be mediated by increased tissue levels of cyclic AMP. Although such an interpretation eventually may be validated, other explanations seem equally plausible. First than an intervention leading to an alteration in one pool need not affect other pools. Thus, activation of phosphorylase need not necessarily be associated with enhanced contractility. Indeed, the results just described could be interpreted as providing evidence favoring the hypothesis that separate pools of cyclic AMP do exist.
As a result of these considerations it appears probable that final proof regarding the role of cyclic AMP as the mediator of any specific cellular function will depend on an analysis of the effects of altering the levels of specific pools of cyclic AMP. Hopefully, further investigations of the adenyl cyclase-cyclic AMP system will provide insight not only into this latter problem and into the precise mechanisms responsible for hormone-cellular interaction, but also into how cardiac failure might interfere with these processes.
